HempFusion Wellness (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 8OO), an industry leader in full-spectrum cannabidiol (“CBD”) hemp-extract wellness products and probiotics, announced its Q1 financial results, for the period ended March 31, 2021. Highlights from the report include consolidated revenue for the company totaling $983,496, an increase of 7.6% over the $913,646 reported in fourth-quarter 2020; DTC sales up 59.3% from Q4 2020, totaling $244,255 as compared to $153,305; B2B net revenue decreased 2.8% to $739,241 from 760,341 in fourth-quarter 2020 with international sales, which totaled $75,994, up from no sales in Q4 2020; and gross profit of $280,205, or 28.5% of net revenue. The company also reported a 42.9% increase in operating expenses, which totaled $6,306,703; the increase was primarily attributed to IPO- (“IPO”), marketing- and digital-related expenses. The company ended the quarter in a strong cash position, holding $17,074,030. In addition, HempFusion pointed to several business highlights in the report, including the completion of a $17 million initial public offering and the commencement of trading its stock on the Toronto Stock Exchange (“TSX”), marking the first time a U.S.-based CBD and wellness products company listed directly on the TSX. The company also launched its Probulin store on Amazon and became the no. 2 most recognized CBD brand in America according to Brightfield Group. “With nearly all international business paused due to COVID throughout 2020 and Q1 2021, and with slower than expected reopenings, the company still achieved an incremental QoQ growth of 7.6%,” said HempFusion co-founder and CEO Jason Mitchell, ND, in the press release. “Now, with vaccine rollouts taking place across the country, we are encouraged with reopening rates and excited that our sales, which currently take place in approximately 75% brick-and-mortar businesses, are beginning to reopen. We remain committed to developing new revenue channels and have entered additional countries including China, Ireland, and the United Kingdom, and we are excited with subsequent quarterly events in which new purchase orders were received, showing early signs of the return of international business. These international POs have the potential to drive millions in revenue.”
To view the full press release, visit https://cnw.fm/6H9mt
About HempFusion Wellness Inc.
HempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition. HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research and HF Labs, to approximately 4,000 retailers across all 50 states of the United States and select international locations. Built on a foundation of regulatory compliance and human safety, HempFusion’s diverse product portfolio comprises 48 SKUs (“SKUs”) including tinctures, proprietary FDA Drug Listed over-the-counter (“OTC”) topicals, doctor/practitioner lines and more. With a strong focus on research and development, HempFusion has an additional 30 products under development. HempFusion is a board member of the US Hemp Roundtable, and HempFusion’s wholly owned subsidiary, Probulin Probiotics, is one of the fastest-growing probiotics companies in the United States, according to SPINs reported data. HempFusion’s CBD products are based on a proprietary Whole Food Hemp Complex(TM) and are available in stores or online. For more information about the company, visit www.HempFusion.com.
NOTE TO INVESTORS: The latest news and updates relating to HempFusion are available in the company’s newsroom at https://cnw.fm/HempFusion
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire is part of the InvestorBrandNetwork.